Luddington R, Baglin T
Department of Haematology, Addenbrooke's NHS Trust, Cambridge, UK.
J Thromb Haemost. 2004 Nov;2(11):1954-9. doi: 10.1111/j.1538-7836.2004.00964.x.
Measurement of thrombin generation by calibrated automated thrombography (CAT) could fulfill the requirements of a global test of coagulability and is potentially applicable to routine clinical laboratory practice. The purpose of this study was to determine if corn trypsin inhibitor (CTI) could be used to abolish contact factor activation in this assay, thus allowing accurate measurement of low tissue factor (TF) concentration-triggered thrombin generation on samples taken in a routine clinical setting.
The endogenous thrombin potential (ETP) was measured by CAT.
The study demonstrated that addition of CTI after plasma separation is not sufficient and blood must be drawn into tubes containing CTI if in-vitro contact factor-activated thrombin generation is to be abolished. Contact factor-activated thrombin generation is completely inhibited at a CTI concentration of 18.3 microg mL(-1) whole blood. Increasing the CTI concentration above this level does not lead to suppression of the TF-triggered ETP. At a TF concentration of 2 pmol, ETPs were significantly lower in the presence of CTI (P < 0.001). The difference (no CTI minus CTI) between results ranged from - 1 to 2159 nM min(-1) (median - 754). Whilst the low concentration TF-ETP assay was not optimized to distinguish degrees of coagulability between patient samples, there was a significant difference in ETP between normal and hemophilia samples and samples from patients with a clinical prothrombotic tendency.
CTI can be applied to ETP measurement by CAT. This permits the use of CAT in a low TF-triggered thrombin generation assay without concern for the effect of interference from in-vitro contact factor activation and the optimum reagent conditions for using CAT as a global test of coagulability in clinical practice can now be defined.
通过校准自动血栓形成分析法(CAT)测量凝血酶生成可满足全面凝血功能检测的要求,并且有可能应用于常规临床实验室实践。本研究的目的是确定玉米胰蛋白酶抑制剂(CTI)是否可用于消除该检测中接触因子的激活,从而能够准确测量在常规临床环境中采集的样本上低组织因子(TF)浓度引发的凝血酶生成。
通过CAT测量内源性凝血酶潜力(ETP)。
研究表明,血浆分离后添加CTI是不够的,如果要消除体外接触因子激活的凝血酶生成,血液必须采集到含有CTI的试管中。在CTI浓度为18.3微克/毫升全血时,接触因子激活的凝血酶生成被完全抑制。将CTI浓度提高到该水平以上不会导致TF触发的ETP受到抑制。在TF浓度为2皮摩尔时,存在CTI的情况下ETP显著降低(P < 0.001)。结果之间的差异(无CTI减去CTI)范围为 -1至2159纳摩尔·分钟⁻¹(中位数 -754)。虽然低浓度TF-ETP检测未优化以区分患者样本之间的凝血程度,但正常样本与血友病样本以及具有临床血栓形成倾向患者的样本之间的ETP存在显著差异。
CTI可应用于通过CAT测量ETP。这使得CAT能够用于低TF触发的凝血酶生成检测,而无需担心体外接触因子激活的干扰影响,并且现在可以确定将CAT用作临床实践中全面凝血功能检测的最佳试剂条件。